New Treatments Offer Relief for Menopausal Hot Flashes, Expert Says
AM730 · 1 SOURCESabout 1 hour ago5 MIN
Summary
Hong Kong emergency medicine specialist Dr. Sham Kin (岑健) has highlighted that menopausal symptoms can begin affecting women in their thirties, during a transitional phase called perimenopause when estrogen levels fluctuate unpredictably rather than decline steadily. Recent research reveals that 40% of women experience significant work performance decline during menopause, with 14% ultimately resigning due to unmanageable symptoms. A new class of non-hormonal medications called NK-3 receptor inhibitors, introduced in Hong Kong last year, offers a promising treatment alternative for moderate to severe cases .
Key Points
- Perimenopause can begin in thirties as estrogen levels rise and fall unpredictably, affecting every organ system including bones, cardiovascular system, and brain
- Metabolic health is a critical factor: women with diabetes or hypertension experience more severe hot flashes than those with healthier metabolisms
- A 50-year-old female executive was forced to resign after multiple embarrassing episodes of uncontrollable facial flushing and sweating during client presentations
- NK-3 receptor inhibitors work by controlling brain glands to lower body temperature, taken once daily with effects visible within one week
- Hormone replacement therapy remains the most direct treatment but is contraindicated for breast cancer survivors without careful oncologist consultation
Why It Matters
With an aging workforce and more women working into their later years, menopause-related productivity losses represent a significant economic and social issue. The availability of new non-hormonal medications provides hope for the estimated 40% of menopausal women struggling with symptoms, potentially allowing them to remain in the workforce longer .
With an aging workforce and more women working into their later years, menopause-related productivity losses represent a significant economic and social issue. The availability of new non-hormonal medications provides hope for the estimated 40% of menopausal women struggling with symptoms, potentially allowing them to remain in the workforce longer .